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ABSTRACT  
Pregnancies resulting in very small or very large babies are at higher risk of obstetric complications with 
increased morbidity for both mother and baby. Using data from the Medical Birth Registry of Norway we 
have shown how human birth weight is still subject to stabilizing selection. Particular combinations of 
maternal/fetal immune genes have been implicated in pregnancies resulting in a low birth weight baby 
(<5th birth weight centile). More specifically, an inhibitory maternal KIRAA genotype with a paternally 
derived fetal HLA-C2 ligand. At the other end of the birth weight spectrum the presence of an activating 
maternal KIR2DS1 gene is associated with increased birth weight in linear or logistic regression analyses of 
all pregnancies >5th centile (p=0.005, OR=2.65). Thus, inhibitory maternal KIR combined with fetal HLA-
C2 is more frequently associated with low birth weight, whereas activating maternal KIR with fetal HLA-
C2 ligand is associated with increasing birth weight. Our findings using the MoBa cohort have replicated 
the association of KIR and HLA-C seen in poor placentation, and confirm the importance of maternal/fetal 
immune gene interactions in determining the outcome of pregnancy. 
 
This is an open access article distributed under the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction 
in any medium, provided the original work is properly cited. 
 
 
Our work aims to understand how the immune system 
contributes to successful pregnancy. The placenta 
forms the interface between the mother and baby in the 
uterus. Fetal extravillous trophoblast cells (EVT) 
invade into the maternal decidua where they remodel 
uterine spiral artery walls converting them into high 
conductance vessels, thus securing a good blood supply 
to the feto-placental unit [1]. Insufficient transforma-
tion of the maternal spiral arteries results in poor 
placental development which consequently gives rise 
to disorders of pregnancy such as pre-eclampsia, fetal 
growth restriction (FGR), still birth and recurrent 
miscarriage [2-4]. Excessive invasion by EVT can also 
be detrimental in cases such as placenta accreta. High 
birth weight is potentially dangerous to both mother 
and baby through prolonged obstructed labour [5,6] 
with risk of asphyxia and injury in the baby [7-9], and 
lacerations and post-partum haemorrhage in the mother 
[5,9]. It is therefore crucially important that this process 
is carefully regulated maintaining a balance between 
over and under invasion. Using data from 795,068 first 
pregnancies resulting in a live birth from the Medical 
Birth Registry of Norway, we plotted the distribution 
of birth weight against frequency of transfer to special 
care baby unit [10]. This illustrated clearly the risk of 
morbidity in neonates at either end of the birth weight 
spectrum, even in a modern medicalised setting (Fig. 1). 
 Large numbers of a specialised type of lymphocyte 
known as uterine NK cells are found in the decidua du-
ring placentation [11]. Uterine NK cells express Killer 
cell Ig-like Receptors (KIR) and fetal EVT express 
their cognate ligand HLA-C, the only classical HLA 
class I molecule found on trophoblast [12]. We have 
proposed that this maternal KIR/fetal HLA-C interac-
tion functions to mediate uterine NK cell control of 
trophoblast invasion [11,13-15]. 
 This receptor ligand interaction is unusual in that 
both KIR and HLA are highly polymorphic gene 
systems. They also segregate independently and are 
encoded on separate chromosomes. KIR genotypes 
vary with content, copy number and at allelic variation 
at individual KIR loci. Around 500 different genotypes 
have already been described to date [16]. To simplify 
this complexity, KIR haplotypes are classified as either 
A or B based on gene content. The KIR A haplotype is 
highly stable, varying little at the gene content level 
and carrying fewer genes. Notably it encodes 
KIR2DL1 and KIR2DL3, both inhibitory receptors for 
HLA-C. The KIR B haplotype is much more variable 
with the potential to encode inhibitory KIR2DL1 and 
KIR2DL2, and also activating KIR2DS1, all of which 
bind HLA-C [11]. 
 HLA-C alleles can be subdivided into two groups 
C1 and C2 based on a dimorphism at position 80 of the 
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Figure 1. Distribution of birth weights in the Norwegian population with percentage 
of babies transferred to the special care baby unit for the years 1967-2010 
(n=795,068).  
(Originally published in The Journal of Immunology. Hiby S, Apps R, Chazara O et 
al.2014. Maternal KIR in combination with paternal HLA-C2 regulate human birth 
weight. J. Immunol. Vol:192:5069-5073. Copyright © [2014] The American 
Association of Immunologists, Inc.) 
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Figure 1.  Distribution of birth weights in the Norwegian population with percentage of babies transferred to the 
special care baby unit for the years 1967-2010 (n=795,068).  (Originally published in Journal of Immunology: Hiby 
S, Apps R, Chazara O, et al. Maternal KIR in combination with paternal HLA-C2 regulate human birth weight. J. 
Immunol 2014; 192: 5069-5073. Copyright © [2014] The American Association of Immunologists, Inc.) 
 
 
α1 domain [17]. In this way KIR distinguish between 
C1 and C2 as mutually exclusive epitopes (Table 1). 
 To determine if maternal KIR and fetal HLA-C 
variation is important in pregnancy we have looked for 
consistent genetic associations of particular maternal 
KIR and fetal HLA-C combinations in a range of ob-
stetric disorders (pre-eclampsia, FGR, and recurrent 
miscarriage) all of which result from defective placen-
tation. All these conditions share a genetic association 
characterised by mothers with two KIR A haplotypes 
(AA genotype), combined with an HLA-C2 group allele 
in the fetus, particularly when the fetal C2 is paternally 
derived. Conversely, women who carry a KIR B haplo-
type encoding KIR2DS1, the activating receptor for 
C2, are significantly protected from these disorders 
when a fetal C2 is present [11,18,19]. 
 Because we were intrigued by the high fetal and 
maternal mortality and morbidity seen in pregnancies 
with high birth weights [5-9] we went on to question 
what maternal KIR and fetal HLA-C combinations 
were associated with these pregnancies. 
 Mother and baby DNA pairs were genotyped for 
KIR and HLA-C from two separate cohorts. From our 
United Kingdom cohort we analysed 747 pre-
eclamptic pregnancies, 118 pregnancies with FGR 
(≤5th birth weight centile) and 404 normal pregnancies 
[10]. Selected from the MoBa cohort [20] were 995 
normal (including 66 >90th birth weight centile), and 
141 pre-eclamptic first pregnancies. 
 Replicating our previous findings from the UK, 
increased maternal KIR AA and low KIR2DS1 frequen-
cies associated with pregnancies with low birth weight 
and/or pre-eclampsia in the MoBa cohort. Conversely, 
high birth weight pregnancies (≥90th centile) had low 
KIR AA and high KIR2DS1 frequencies [10]. 
 The effect of KIR2DS1 on birth weight was tested 
in both categorical and continuous analysis. Using 
birth weight in grams as a continuous variable, the 
presence of a maternal KIR2DS1 conferred an average 
birth weight increase of 78g (p=0.005) in a linear 
regression model. The frequency of maternal KIR2DS1 
was significantly higher in pregnancies with high com-
pared with median birth weight in categorical analysis 
(Table 2, [10]). 
 The effect of KIR AA genotypes on pre-eclampsia 
and FGR was previously observed particularly in preg-
nancies with a fetus carrying a paternally derived C2. 
This was shown by both categorical and continuous 
analysis across the birth weight spectrum. The effect 
of maternal KIR2DS1 on birth weight is thus depen-
dent on the presence of fetal C2, particularly paternally 
derived fetal C2. 
 In other words the presence of fetal C2 amplifies 
the effect of maternal KIR2DS1. When the fetus has 
more C2 groups than the mother (C1/C2 fetus with 
C1/C1 mother, and C2/C2 fetus with C1/C2 mother), 
an average increase of 245g (p=0.002) was seen. 
Furthermore, presence or absence of KIR2DS1 as a 
categorical variable when combined with more C2 in 
the fetus showed that maternal KIR2DS1 has a signi-
ficant effect when the fetus is carrying more C2 than 
the mother, (OR 2.93, 95% CI 1.66-5.18, p=0.0002). 
In pregnancies where the fetus was C1/C2 we could 
determine parent of origin of the C2 group. In both 
categorical and continuous analyses, the presence of 
maternal KIR2DS1 only has an effect on birth weight 
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Table 1.  KIR known to bind HLA-C and their HLA-C ligands. 
 
KIR HLA-C Ligand KIR Haplotype location Activating/Inhibitory 
2DL1 C2 A and some B Inhibitory 
2DL2 C1, some C2 B Inhibitory 
2DL3 C1 A Inhibitory 
2DS1 C2 B Activating 
2DS2 Possibly C1 B Activating 
2DS4 Some C1 and some C2 A (often deleted) Activating 
 
 
Table 2.  Presence of maternal KIR2DS1 associates with increased birth weight in both categorical and 
continuous analysis n=1316. This is enhanced when the fetus has more HLA-C2 epitopes than the mother 
n=304 and specifically paternally derived C2 n=204. Data summarised from tables I, II, and IV-VII in Hiby 
S, Apps R, Chazara O, et al. Maternal KIR in combination with paternal HLA-C2 regulate human birth 
weight. J. Immunol 2014; 192: 5069-5073. 
 
   Continuous analysis 
  Weight         p-value 
      Categorical analysis 
  OR      95% CI      p-value 
Presence of maternal KIR2DS1      78 g  é       0.005  1.38    1.07-1.79      0.01 
Maternal KIR2DS1 with more C2 in fetus than mother   245 g  é       0.0002  2.93    1.66-5.18      0.0002 
Maternal KIR2DS1 with paternally derived fetal C2   196 g  é       0.016  2.65    1.33-5.26      0.005 
 
 
when the fetal C2 is paternally derived (paternal C2 
p=0.016, maternal C2 p=0.75) (Table 2). 
 Our findings using MoBa subjects have replicated 
the association of KIR and HLA-C with poor placenta-
tion (pre-eclampsia, and low birth weight) and confirm 
the importance of maternal KIR/fetal HLA-C interac-
tions in determining the outcome of pregnancy. Of 
importance is that we now also show an effect in high 
birth weight pregnancies, implicating a role in the 
regulation of placentation in normal or excessive 
invasion. This effect has a clear direct impact on birth 
weight as a continuous variable, with an effect compa-
rable or even greater than smoking during pregnancy, 
high altitude and sex of the baby [21-24]. 
 KIR2DS1 is expressed by uterine NK cells and is 
functional although ascertaining exactly how NK cells 
operate to subtly define the extent of arterial transfor-
mation by trophoblast is an exciting challenge for the 
future. Nonetheless our findings indicate that a balance 
of KIR inhibitory and activating stimuli is necessary 
for optimal trophoblast invasion. NK derived cytokines 
such as GM-CSF, released in response to activation of 
KIR2DS1 by binding C2, are one possible mechanism 
[13]. 
 Not all women with KIR AA genotypes and fetal C2 
have a pregnancy disorder. We are now selecting 
patients from the MoBa cohort to study women who 
have recurrent pre-eclampsia as well as those who 
have a normal pregnancy followed by a pre-eclamptic 
pregnancy and vice versa. We aim to focus on 
KIR2DL1, the inhibitory KIR for HLA-C2 because 
there are 4 different KIR2DL1 alleles in the Norwegian 
population. Our prediction is that particular KIR2DL1 
alleles will confer most risk. 
 Perhaps in the long term KIR/HLA-C genotyping 
might be a genetic predictor of birth weight to identify 
those at risk of FGR, pre-eclampsia or macrosomia. 
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